Novartis AG Registered Shares NVSEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVSEF is a good fit for your portfolio.
News
-
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
-
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
-
Trending: Novartis Shares Climb on Guidance Lift
-
Novartis Raises Guidance on Profit, Sales Growth — Update
-
Novartis shares jump as drugmaker boosts outlook
-
Novartis Raises Guidance on Profit, Sales Growth
-
Novartis Gets Priority Review for Kidney Disease Treatment
-
Trending: Novartis Begins Tender Offer for MorphoSys Shares
Trading Information
- Previous Close Price
- $95.11
- Day Range
- $95.36–96.74
- 52-Week Range
- $90.24–108.50
- Bid/Ask
- $95.10 / $100.09
- Market Cap
- $195.88 Bil
- Volume/Avg
- 52,316 / 95,885
Key Statistics
- Price/Earnings (Normalized)
- 13.91
- Price/Sales
- 3.99
- Dividend Yield (Trailing)
- 3.92%
- Dividend Yield (Forward)
- 4.46%
- Total Yield
- 7.37%
Company Profile
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 76,057
- Website
- https://www.novartis.com
Competitors
Valuation
Metric
|
NVSEF
|
GSK
|
JNJ
|
---|---|---|---|
Price/Earnings (Normalized) | 13.91 | 10.66 | 14.07 |
Price/Book Value | 4.94 | 4.80 | 5.14 |
Price/Sales | 3.99 | 2.24 | 4.12 |
Price/Cash Flow | 13.24 | 10.68 | 18.53 |
Price/Earnings
NVSEF
GSK
JNJ
Financial Strength
Metric
|
NVSEF
|
GSK
|
JNJ
|
---|---|---|---|
Quick Ratio | 0.61 | 0.59 | 0.91 |
Current Ratio | 0.90 | 0.88 | 1.16 |
Interest Coverage | 11.32 | 9.30 | 18.88 |
Quick Ratio
NVSEF
GSK
JNJ
Profitability
Metric
|
NVSEF
|
GSK
|
JNJ
|
---|---|---|---|
Return on Assets (Normalized) | 13.39% | 10.54% | 13.98% |
Return on Equity (Normalized) | 31.09% | 50.48% | 35.02% |
Return on Invested Capital (Normalized) | 19.67% | 21.33% | 22.24% |
Return on Assets
NVSEF
GSK
JNJ
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Rhlntmxnx | Jwr | $697.4 Bil | |
JNJ
| Johnson & Johnson | Hqnnyclyp | Rcthm | $353.8 Bil | |
MRK
| Merck & Co Inc | Rynrsqjl | Wkfqk | $332.3 Bil | |
ABBV
| AbbVie Inc | Nypyrjzjc | Sppy | $282.6 Bil | |
AZN
| AstraZeneca PLC ADR | Lfdpqnry | Rsmx | $232.3 Bil | |
NVS
| Novartis AG ADR | Fcptybw | Dwlqs | $200.1 Bil | |
RHHBY
| Roche Holding AG ADR | Wccfgcvkl | Mnxkv | $195.3 Bil | |
AMGN
| Amgen Inc | Jcngyqxxh | Bqq | $144.5 Bil | |
PFE
| Pfizer Inc | Rdhbkwwn | Jcsp | $143.8 Bil | |
SNY
| Sanofi SA ADR | Ygxjlrpl | Tqbk | $122.2 Bil |